拟定适应症(或功能主治)：本品适用于在控制饮食和增加运动基础上，初始体重指数(BMI)符合以下要 求的成人的长期体重管理：≥28kg/m2(肥胖)，或≥24kg/m2(超重)并伴有至少一种体重相关合并症(例如高 血糖、高血压、血脂异常、阻塞性睡眠呼吸暂停、脂肪肝等)。 智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司福建盛迪医药有限公司收到国家 药品监督管理局(简称"国家药监局")下发的《受理通知书》，公司HRS9531注射液的药品上市许可申请 获国家药监局受理。 ...

Core Viewpoint - Heng Rui Medicine has received conditional approval from the National Medical Products Administration for its self-developed innovative drug, SHR2554 tablets, for adult patients with relapsed or refractory peripheral T-cell lymphoma who have received at least one line of systemic therapy [1] Group 1: Product Development - SHR2554 tablets are the first self-developed EZH2 inhibitor in China [1] - The drug is a new, efficient, and selective oral EZH2 inhibitor [1] - The total R&D investment for the SHR2554 project has reached approximately 213 million yuan [1] Group 2: Market Context - In January 2020, the U.S. FDA approved the oral EZH2 inhibitor Tazverik (tazemetostat) developed by Epizyme [1] - In August 2021, Hutchison China MediTech obtained the development and commercialization rights for tazemetostat in Greater China [1] - Tazverik's global sales are projected to be approximately 51 million USD in 2024 according to EvaluatePharma [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the drug listing application of HRS9531 injection, indicating progress in the company's product pipeline and potential market entry for a new diabetes treatment [1] Company Summary - HRS9531 injection is a novel dual agonist targeting GLP-1R and GIPR, with global independent intellectual property rights [1] - The drug aims to regulate glucose and lipid metabolism, suppress appetite, and enhance insulin sensitivity, thereby improving blood sugar levels and aiding weight loss [1]

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-133 江苏恒瑞医药股份有限公司 关于获得药品注册批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）的通知，附条件批准公司自主研发的 1 类创 新药泽美妥司他片（SHR2554 片）上市，用于既往接受过至少 1 线系统性治疗的 复发或难治外周 T 细胞淋巴瘤（R/R PTCL）成人患者。泽美妥司他片是中国首个 自主研发的 EZH2 抑制剂，现将相关情况公告如下： 一、药品的基本情况 药品名称：泽美妥司他片 剂型：片剂 规格：50mg 注册分类：化学药品 1 类 批准的适应症：用于既往接受过至少 1 线系统性治疗的复发或难治外周 T 细胞淋巴瘤成人患者。 二、药品的其他情况 外周 T 细胞淋巴瘤（PTCL）是一组具有高度异质性和侵袭性的淋巴系统恶性 肿瘤，在我国非霍奇金淋巴瘤患者中，其占比约 25-30% [1]，明显高于西方国家； 且患者中位发病年龄为 ...

药品名称：HRS9531 注射液 剂型：注射剂 受理号：CXHS2500106、CXHS2500107、CXHS2500108、CXHS2500109、 CXHS2500110、CXHS2500111、CXHS2500112、CXHS2500113、CXHS2500114 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-134 江苏恒瑞医药股份有限公司 关于药品上市许可申请获受理的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司福建盛迪医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）下发的《受理 通知书》，公司 HRS9531 注射液的药品上市许可申请获国家药监局受理。现将相 关情况公告如下： 一、药品的基本情况 药品从研制、临床试验报批到投产的周期长、环节多，药品研发及至上市容 易受到一些不确定性因素的影响，敬请广大投资者谨慎决策，注意防范投资风险。 公司将按国家有关规定积极推进上述研发项目，并及时对项目后续进展情况履行 信 ...

恒瑞医药公告，公司子公司福建盛迪医药有限公司的HRS9531注射液的药品上市许可申请已获国家药品 监督管理局受理。HRS9531注射液用于成人的长期体重管理，适用于初始体重指数≥28kg/m 的肥胖患 者，或BMI≥24kg/m 且伴有至少一种体重相关合并症的超重患者。在2025年7月的Ⅲ期临床试验中，该 药物达到了主要及所有关键次要研究终点，表现出良好的安全性和耐受性。目前，HRS9531项目累计研 发投入约4.52亿元。公司将按照国家有关规定推进项目研发，并及时披露进展情况。 ...

Group 1 - The chemical pharmaceutical sector increased by 3.54% on September 1, with Maiwei Biotech leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] - Notable gainers in the chemical pharmaceutical sector included Maiwei Biotech, which rose by 20.00% to a closing price of 57.60, and Xingqi Eye Medicine, which increased by 14.65% to 77.54 [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 1.245 billion yuan from main funds, while retail funds experienced a net outflow of 41.1167 million yuan [2] - The top stocks by main fund inflow included Heng Rui Medicine with 474 million yuan and Fuxing Medicine with 256 million yuan [3] - Conversely, stocks like Duorui Medicine and ST Suwu experienced significant declines, with Duorui Medicine down 9.36% to 41.17 [2][3]

FF301 致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 公司名稱: 江蘇恒瑞醫藥股份有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01276 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 258,197,600 | RMB | | 1 RMB | | 258,197,600 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 258,197,600 | RMB | | 1 RMB | | 258,197,600 | | 2. 股份分類 | 普通股 | 股份類別 | A ...

每经AI快讯，有投资者在投资者互动平台提问： 请问2025年上半年扣除对外许可收入后的营业额和利 润增长率是多少？ 恒瑞医药（600276.SH）9月1日在投资者互动平台表示，公司2025年上半年营业收入157.6亿元，其中对 外许可收入19.9亿元。公司归属于上市公司股东的净利润44.5亿元，同比增长29.7%。详细信息请查阅 公司2025年半年度报告"经营情况的讨论与分析"部分内容。 （文章来源：每日经济新闻） ...

Group 1 - The article highlights the top three companies with the highest AH premium rates as Northeast Electric (00042) at 785.25%, Hongye Futures (03678) at 247.54%, and Andeli Juice (02218) at 235.17% [1] - The bottom three companies with the lowest AH premium rates include Ningde Times (03750) at -13.42%, Hengrui Medicine (01276) at 2.98%, and Midea Group (00300) at 5.69% [1] - The article also lists the companies with the highest deviation values, with Jinli Permanent Magnet (06680) at 38.75%, Beijing Machinery (00187) at 24.13%, and Zhejiang Shibao (01057) at 20.83% [1] Group 2 - The top ten AH stocks by premium rate include Fudan Zhangjiang (01349) at 227.99% and Sinopec Oilfield Service (01033) at 217.95% [1] - The bottom ten AH stocks by premium rate include Zijin Mining (02899) at 5.95% and China Merchants Bank (03968) at 8.52% [1] - The article provides a detailed table of the top and bottom AH stocks, including their H-share prices, A-share prices, premium rates, and deviation values [1][2]